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Abstract: The topoisomerase I inhibitor topotecan is the only single-agent therapy approved for 
the treatment of recurrent small cell lung cancer (SCLC). Many patients with recurrent SCLC 
may be predisposed to treatment-related adverse events because of the presence of comorbidi-
ties such as advanced age, renal impairment, or extensive prior therapy. In this setting, disease 
stabilization is considered a treatment beneﬁ  t, and quality-of-life effects and toxicity proﬁ  les of 
treatments should be considered. The approved regimen of topotecan 1.5 mg/m2 on days 1 to 5 of 
a 21-day cycle is active and has generally mild nonhematologic toxicity and a well-established 
hematologic toxicity proﬁ  le characterized by reversible, manageable, and noncumulative neu-
tropenia. Alternative dosing and treatment schedules may lower the incidence of hematologic 
toxicities while maintaining antitumor efﬁ  cacy in this patient population. Therefore, topotecan 
may provide physicians with an effective and versatile therapeutic option for the treatment of 
patients with relapsed SCLC.
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Introduction
Lung cancer is the most common cancer worldwide, with an estimated 174,470 new 
cases diagnosed and 162,460 deaths in the United States in 2006 alone (Jemal et al 
2006). Non-small cell lung cancer is the leading cause of cancer-related death in both 
men and women and frequently presents as advanced disease (Ho et al 2006). Conse-
quently, most patients with non-small cell lung cancer are treated with palliative therapy 
(Ho et al 2006). Docetaxel, pemetrexed, and erlotinib are approved for second-line 
use, and oral topotecan, polyglutamated paclitaxel, and geﬁ  tinib have been evaluated 
in phase III trials (Ho et al 2006). Small cell lung cancer (SCLC), which accounts for 
approximately 18% of all lung cancers in the United States, is typically an aggressive 
disease with a high incidence of early and distant metastases (Ardizzoni 2004). Most 
patients with SCLC are not diagnosed until their cancer is in an advanced stage, and 
the majority of cases are unresectable. Consequently, ﬁ  rst-line therapies are typically 
aggressive, especially for limited-stage disease. Although several agents are active 
against SCLC and initial response rates to standard ﬁ  rst-line therapies are as high as 
90% in patients with limited-stage disease, most patients with SCLC experience disease 
relapse (Okuno and Jett 2002). The 5-year disease-free survival rate is 5% to 10% 
in this patient population, and relapsed SCLC is considered a chronic disease state 
by some physicians in the ﬁ  eld (Ardizzoni 2004). As such, symptom palliation is an 
important endpoint for patients with extensive-stage disease, and stable disease may 
be considered a treatment beneﬁ  t. Therefore, effective and well-tolerated agents that 
differ from those of therapeutic regimens used in the ﬁ  rst-line setting are required.
Management of relapsed SCLC can be challenging for many reasons. 
Approximately 70% of patients diagnosed with lung cancer in the United States 
are 65 years old and have comorbidities (eg, impaired pulmonary, hepatic, or renal Therapeutics and Clinical Risk Management 2007:3(6) 1088
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function or poor performance status) that may limit the use 
of aggressive therapies such as platinum-based combination 
regimens (Hurria and Kris 2003; Ardizzoni 2004; Garst et al 
2005). Moreover, administration of many ﬁ  rst-line thera-
pies results in cumulative toxicities, which may reduce the 
patient’s ability to tolerate subsequent lines of therapy. There-
fore, patients with relapsed SCLC may require dose delays, 
dose reductions, and hematopoietic growth factor support 
during therapy. Currently, second-line therapies for SCLC 
include cyclophosphamide, doxorubicin, and vincristine 
(CAV); single-agent topotecan; and single-agent etoposide 
(Ardizzoni 2004; Ciombor and Rocha Lima 2006). Although 
combination therapies may improve the overall response rate 
(ORR) compared with single-agent therapies, the duration 
of response remains limited, and the utility of combination 
regimens may also be limited because of the potential for 
overlapping or cumulative toxicities (Ardizzoni 2004).
Single-agent therapies are therefore an attractive option 
for the treatment of relapsed SCLC. Topotecan (Hycamtin®; 
GlaxoSmithKline, Research Triangle Park, North Carolina, 
USA) is the only approved single-agent therapy for relapsed 
SCLC and has demonstrated significant pain palliation 
compared with CAV in this setting (von Pawel et al 1999; 
Hycamtin 2006). In patients with relapsed SCLC, topote-
can produced ORRs of 14% to 38% in platinum-sensitive 
SCLC and 2% to 11% in platinum-resistant SCLC, with 
an additional 17% to 20% of patients achieving stable 
disease (Perez-Soler et al 1996; Ardizzoni et al 1997; von 
Pawel et al 1999). Moreover, topotecan is associated with 
generally mild nonhematologic toxicities and manageable, 
noncumulative, reversible neutropenia (Hycamtin 2006). 
Therefore, the efﬁ  cacy and tolerability of topotecan provide 
physicians with a viable therapeutic option in the treatment 
of relapsed SCLC.
Safety proﬁ  le of topotecan
Topotecan, a topoisomerase I inhibitor with broad antitumor 
activity, is currently approved in more than 70 countries for 
the second-line treatment of metastatic ovarian cancer and in 
more than 30 countries for the treatment of platinum-sensitive 
relapsed SCLC (Armstrong et al 2005). This agent was also 
recently approved in the United States for the treatment of 
stage IVB recurrent or persistent cervical cancer not ame-
nable to curative procedures (Hycamtin 2006). Topotecan 
binds to topoisomerase I and forms a complex on the DNA, 
thereby leading to double-stranded DNA breaks during DNA 
replication and, ultimately, cell death (Figure 1) (Rothenberg 
1997). This unique mechanism of action makes topotecan a 
valuable tool in many treatment regimens. Of note, topotecan 
is the only approved single-agent regimen that has demon-
strated symptom palliation in patients with SCLC, improving 
dyspnea, anorexia, hoarseness, fatigue, and interference with 
daily activities (von Pawel et al 1999).
Topotecan is generally well tolerated, with nonhemato-
logic toxicities that include nausea, vomiting, and dyspnea 
and are generally mild to moderate in severity (Treat et al 
2004). The hematologic proﬁ  le includes dose-limiting neu-
tropenia that is noncumulative, reversible, and generally 
manageable with dose reductions, treatment delays, and 
growth factor support (Figure 2) (Armstrong et al 2005). 
Other grade 3/4 hematologic toxicities include thrombocy-
topenia and anemia (Armstrong et al 2005).
Topotecan is approved for use in patients with SCLC who 
have adequate bone marrow reserves (baseline neutrophil 
count of 1.5 × 109/L and platelet count of 100 × 109/L) 
(Hycamtin 2006). Recovery of cell counts after treatment-
induced suppression may be achieved with growth factor sup-
port, such as granulocyte colony-stimulating factor (G-CSF), 
or transfusion (Armstrong and O’Reilly 1998; Hycamtin 
2006). If treatment is delayed because of prolonged myelo-
suppression, dose reductions in 0.25 mg/m2 increments can 
be considered (Armstrong and O’Reilly 1998).
A recent integrated analysis of topotecan for the treatment 
of SCLC and ovarian cancer identiﬁ  ed several risk factors 
for hematologic toxicity during the ﬁ  rst course of treatment, 
including extensive prior chemotherapy, advanced age, 
and impaired creatinine clearance (Armstrong et al 2005). 
Previous therapies and advanced age may affect bone marrow 
reserves, and impaired renal function may result in lower 
clearance rates of topotecan, thereby prolonging exposure. 
Furthermore, many patients with SCLC have prior exposure 
to agents that have cumulative myelotoxicity and nephrotox-
icity (eg, platinum-based regimens) as ﬁ  rst-line treatments, 
and the initiation of topotecan treatment at a reduced starting 
dose may be warranted in these patients.
Standard dosing regimen
Topotecan 1.5 mg/m2 on days 1 to 5 of a 21-day cycle is an 
approved treatment regimen for recurrent SCLC (Hycamtin 
2006). At this dose, topotecan has demonstrated antitumor 
activity in both chemosensitive (deﬁ  ned in phase III studies 
as disease responding to chemotherapy but subsequently 
progressing = 60-days after chemotherapy and in phase II 
studies as disease responding to chemotherapy but subse-
quently progressing = 90-days after chemotherapy) and 
chemoresistant SCLC (Hycamtin 2006).Therapeutics and Clinical Risk Management 2007:3(6) 1089
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comparable between groups (topotecan, 70%; CAV , 72%). 
Grade 4 thrombocytopenia (topotecan, 29%; CAV , 5%) and 
grade 3/4 anemia (topotecan, 41%; CAV , 19%) were more 
frequently reported in patients treated with topotecan than in 
patients treated with CAV (von Pawel et al 1999). Notably, 
greater symptom palliation was observed in patients treated 
with topotecan than in those treated with CAV for dyspnea 
(p = 0.002), anorexia (p = 0.042), hoarseness (p = 0.043), 
fatigue (p = 0.032), and interference with daily activities 
(p = 0.023; von Pawel et al 1999). Therefore, topotecan and 
CAV had similar efﬁ  cacy and tolerability, but topotecan 
was superior to CAV in providing symptom palliation, an 
important consideration for maintaining quality of life (QOL) 
throughout the continuum of care.
Recently, the efﬁ  cacy and safety of topotecan (1.5 mg/m2 
on days 1 to 5 of a 21-day cycle) were retrospectively ana-
lyzed using patient data from 5 large phase II and III trials of 
relapsed SCLC (Table 1) (Eckardt et al 1996; Ardizzoni et al 
1997; Depierre et al 1997; von Pawel et al 1999; von Pawel 
et al 2001; Treat et al 2004). The ORR was 15%, although 
In a pivotal, multicenter, phase III trial in patients 
with recurrent SCLC, patients were randomized to receive 
topotecan or CAV combination therapy (von Pawel et al 
1999). Although CAV is not a standard second-line therapy 
for SCLC, its toxicity and efﬁ  cacy proﬁ  le is well estab-
lished, and the therapy has been widely used. In this trial, 
a total of 446 courses of topotecan and 359 courses of 
CAV were administered to 107 and 104 patients, respec-
tively (von Pawel et al 1999). The ORR (topotecan, 24%; 
CAV , 18%) and median overall survival (mOS; topotecan, 
25.0-weeks; CAV , 24.7-weeks) were similar in patients 
treated with topotecan compared with patients treated with 
CAV (von Pawel et al 1999). Moreover, the median time 
to response (topotecan, 6.0-weeks; CAV , 6.1-weeks), time 
to progression (topotecan, 13.3-weeks; CAV , 12.3-weeks), 
and response duration (topotecan, 14.4-weeks; CAV , 
15.3-weeks) were similar between groups (von Pawel et al 
1999). Furthermore, the toxicity proﬁ  le was similar for both 
arms. Hematologic toxicity was the most common toxicity 
in both arms, and reports of high-grade neutropenia were 
Figure 1 Mechanism of action of topotecan. Copyright © 1997. Reprinted with permission from Rothenberg ML. 1997. Topoisomerase I inhibitors: review and update. Ann 
Oncol, 8:837–55.Therapeutics and Clinical Risk Management 2007:3(6) 1090
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patients with chemosensitive disease had a higher ORR 
than patients with chemoresistant/chemorefractory disease 
(19% versus 4%, respectively) (Table 2) (Treat et al 2004). 
Moreover, stable disease, which is also considered a beneﬁ  t 
of treatment in this patient population, was experienced by 
20% of patients (22% of patients with chemosensitive disease 
and 16% of patients with chemoresistant disease) (Treat et al 
2004). Neutropenia and leukopenia, though transient, were 
the most commonly reported grade 3/4 hematologic toxici-
ties, experienced by 90% and 82% of patients, respectively 
(Treat et al 2004). Transient grade 3/4 thrombocytopenia 
and anemia were experienced by 55% and 33% of patients, 
respectively. Nonhematologic toxicities were generally mild 
to moderate and included dyspnea (12%) and asthenia (8%). 
Similar to the pivotal phase III trial (von Pawel et al 1999), 
this study found that, in the 3 trials that evaluated symptom 
palliation, topotecan treatment was associated with palliation 
of a variety of symptoms including dyspnea, cough, chest 
Figure 2 Median neutrophil nadirs by treatment course, dose, and granulocyte-colony stimulating factor (G-CSF). After the ﬁ  rst course, patients may have received G-CSF or reduced 
doses of topotecan; some patients may have discontinued topotecan because of myelosuppression. Copyright © 2005. Reprinted with permission from Armstrong DK, Spriggs 
D, Levin J, et al. 2005. Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis. Oncologist, 10:686–94.
Table 1 Topotecan SCLC trials included in an integrated analysis
Study Phase  Patientsa, n
Ardizzoni et al (1997)  II  101
Eckardt et al (1996)  II  99
von Pawel et al (2001)  II  54b
Depierre et al (1997)  II  119
von Pawel et al (1999)  III  107
Note: aPatients from all trials received the US Food and Drug Administration-
approved dose and schedule of topotecan (1.5 mg/m2 on days 1 to 5 of a 21-day 
cycle); bNumber of patients in the intravenous arm of a randomized study who 
were treated with the US Food and Drug Administration-approved dose of topote-
can. Adapted with permission from Treat et al (2004).
Abbreviation: SCLC, Small cell lung cancer.
Table 2 Antitumor response in the intent-to-treat population in 
a pooled analysis of patients with SCLC
Response Patients,  n(%)
 Overall  Chemosen-  Chemoresistant/
 N  = 479  sitive  Chemorefractory
   n  = 330  n = 149
Objective response   70 (14.6)  64 (19.4)  6 (4.0)
  Complete response  14 (2.9)  12 (3.6)  2 (1.3)
  Partial response  56 (11.7)  52 (15.8)  4 (2.7)
Stable disease  97 (20.3)  73 (22.1)  24 (16.1)
Progressive disease  257 (53.7)  158 (47.9)  99 (66.4)
Not determined  55 (11.5)  35 (10.6)  20 (13.4)
Abbreviation: SCLC, Small cell lung cancer.
Data from Treat et al (2004). Therapeutics and Clinical Risk Management 2007:3(6) 1091
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pain, anorexia, insomnia, and interference with daily activi-
ties (Table 3) (Treat et al 2004).
Although the standard 5-day topotecan regimen is gener-
ally active and well tolerated, heavily pretreated patients and 
patients with comorbidities may be predisposed to adverse 
events (Armstrong et al 2005). Patients with advanced SCLC 
generally have a poor prognosis and may beneﬁ  t from regi-
mens that are more convenient and have improved tolerability 
compared with the standard regimen. Patients may have QOL 
beneﬁ  ts even in the absence of objective responses if disease 
stabilization and symptom palliation occur. Accordingly, 
investigations have been undertaken to assess the value of 
alternative regimens and dosing strategies of topotecan.
Alternative dosing regimens
Multiple treatment regimens and dosing strategies of topote-
can have been investigated to optimize tolerability and con-
venience while maintaining antitumor efﬁ  cacy. A summary 
of topotecan treatment regimens and associated responses is 
presented in Table 4 and Figure 3 (Perez-Soler et al 1996; 
von Pawel et al 1999; Koschel et al 2000; Ogawara et al 
2000; Ardizzoni et al 2003; Takeda et al 2003; Treat et al 
2004; Christodoulou et al 2006; Murphy et al 2006; Shipley 
et al 2006).
Low-dose topotecan
Reductions in the standard topotecan dose may improve 
hematologic toxicities and the need for treatment delays in 
patients with risk factors for myelosuppression (eg, advanced 
age, extensive pretreatment, prior platinum therapy or radia-
tion therapy, and renal impairment) (Armstrong et al 2005). 
For example, in a phase II, single-arm, multicenter trial of 
low-dose topotecan (1.25 mg/m2 on days 1 to 5 of a 21-day 
cycle) in patients with SCLC (N = 171), the reported ORR 
(15%) and median overall survival ([mOS] 22.4-weeks) 
were similar to results reported in studies using the standard 
regimen (Koschel et al 2000). Importantly, the rate of 
myelosuppression was substantially reduced compared with 
myelosuppression rates reported in studies using the standard 
regimen, with grade 3/4 neutropenia, thrombocytopenia, and 
anemia reported in 10%, 5%, and 1% of cycles, respectively 
(Koschel et al 2000). Furthermore, no high-grade nonhema-
tologic toxicities were reported. Similar ORRs (11%) were 
reported with this regimen in a trial of topotecan in patients 
with etoposide- and cisplatin-refractory SCLC (N = 28) 
(Perez-Soler et al 1996). Moreover, 17% of patients achieved 
stable disease, and the mOS was 20-weeks (Perez-Soler et al 
1996). A higher incidence of grade 3/4 myelosuppression 
was reported in this trial than that reported in the Koschel 
et al study (2005), with grade 3/4 granulocytopenia and 
thrombocytopenia occurring after 70% and 31% of cycles, 
respectively (Perez-Soler et al 1996). This increased inci-
dence of high-grade hematologic toxicity compared with 
the toxicity associated with other low-dose regimens may be 
related to previous cisplatin therapy, a known risk factor for 
myelosuppression. Even with the high incidence of myelo-
suppression in this trial, there were no withdrawals because 
of drug-related toxicity, and toxicity was reversible, with 
recovery from thrombocytopenia occurring within 21-days 
in most cases (Perez-Soler et al 1996). No grade 3/4 nonhe-
matologic toxicities were reported (Perez-Soler et al 1996).
Topotecan doses as low as 1.0 mg/m2 have demonstrated 
efﬁ  cacy in the treatment of recurrent SCLC. For example, 
treatment of patients with advanced SCLC with low-dose 
topotecan (1.0 mg/m2 on days 1 to 5 of a 21-day cycle) was 
reported to produce response rates comparable with those 
that have been reported for standard therapy (26%) (Ogawara 
et al 2000). Moreover, the mOS (35.1-weeks) and the median 
1-year survival rate (32%) were consistent with those seen 
in trials of other approved regimens in this setting (Ogawara 
et al 2000). Notably, no grade 4 nonhematologic toxicities 
were observed (Ogawara et al 2000). In a similar phase II 
trial of topotecan (1.0 mg/m2 on days 1 to 5 of a 21-day 
cycle) in patients with relapsed SCLC (N = 50), the ORR was 
26% and the mOS was 262-days (37.4-weeks) (Takeda et al 
2003). Although myelosuppression (leukopenia, neutropenia, 
anemia, and thrombocytopenia) was the most commonly 
reported toxicity, it was generally manageable and there were 
few associated complications (Takeda et al 2003).
Table 3 Proportion of patients with SCLC treated with topote-
can who had symptom improvement
Symptom Patients  showing 
 improvement, 
  n (%) N = 260a
Insomnia 51  (19.6)
Cough 46  (17.7)
Anorexia 45  (17.3)
Dyspnea 41  (15.8)
Chest pain  31 (11.9)
Hoarseness 30  (11.5)
Hemoptysis 9  (3.5)
Interference with  26 (16.1)
daily activitiesb
Fatigueb 22  (13.7)
Note: aSymptom palliation was evaluated in only 3 of the 5 trials in this retrospective 
study; bEvaluated in only 2 of the 3 trials (N = 161).
Data from Treat et al (2004).Therapeutics and Clinical Risk Management 2007:3(6) 1092
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The administration of topotecan at the low doses of 
1.0 mg/m2 and 1.25 mg/m2 results in efﬁ  cacy comparable 
with that of the standard dosing regimen and a lower inci-
dence of treatment-related adverse events. Therefore, low-
dose topotecan therapy may be appropriate for patients who 
exhibit risk factors for treatment-related myelosuppression 
such as advanced age, extensive pretreatment, or renal 
impairment.
Weekly topotecan
Weekly schedules of topotecan have also been investigated 
with the intention of minimizing myelosuppression, dose 
reductions, and treatment delays associated with the standard 
5-day regimen. Moreover, a weekly dosing regimen may 
provide a greater convenience to patients receiving topotecan 
in combination with other agents administered on a weekly 
basis, such as gemcitabine. This regimen is generally active 
and well tolerated in patients with recurrent SCLC, and only 
moderate myelosuppression is typically observed in response 
to the weekly administration of topotecan.
Weekly topotecan (4 mg/m2 for 12 consecutive weeks) 
was associated with comparable activity and a lower inci-
dence of myelosuppression compared with published results 
of the standard 5-day regimen (Shipley et al 2006). In patients 
with either chemosensitive or chemoresistant SCLC (N = 81), 
the ORR was 5%, and stable disease was experienced by 28% 
of patients (Shipley et al 2006). Patients with chemosensitive 
SCLC were approximately twice as likely to respond to this 
weekly topotecan regimen versus patients with chemore-
sistant disease (6% versus 3%, respectively); however, the 
mOS (4.5-months [19.4-weeks]) was comparable between 
treatment groups (chemosensitive, 5.6-months [24.1-weeks]; 
chemoresistant, 3.2-months [13.8-weeks]; p = 0.05) (Shipley 
et al 2006). Grade 3/4 neutropenia or thrombocytopenia was 
observed in 17 (21%) and 22 (27%) patients, respectively 
(Shipley et al 2006).
Results of a phase II study of weekly topotecan (4 mg/m2 
for 12-weeks) also suggested that this regimen is active and 
well tolerated in patients with untreated extensive SCLC 
who were elderly with poor performance status or severe 
coexistent medical illness (N = 39) (Murphy et al 2006). Of 
31 evaluable patients, 4 (13%) patients experienced a partial 
response and 20 (65%) patients experienced stable disease. 
Grade 3/4 thrombocytopenia occurred in 3 (10%) patients, 
and grade 3/4 neutropenia occurred in 11 (35%) patients 
(Murphy et al 2006).
Table 4 Efﬁ  cacy and safety of various topotecan treatment regimens
Study Regimen  Efﬁ  cacy responses  Grade 3/4 hematologic toxicities, %
     ORR, %  mOS, weeks  Neutropenia  Thrombocytopenia  Anemia
von Pawel  1.5 mg/m2 days 1–5  24  25.0  70  29  41
et al (1999)  of 21-day cycle
Treat et al  1.5 mg/m2 days 1–5  15  16.0–36.3b 90  55  33
(2004)a  of 21-day cycle
Koschel et al  1.25 mg/m2 days 1–5  15  22.4  10c 5 c 1 c
(2000)  of 21-day cycle
Perez-Soler 1.25  mg/m2 days 1–5  11  20.0  NR  31c   NR
et al (1996)  of 21-day cycle
Ogawara et al  1.0 mg/m2 days 1–5  26  35.1  84  42  46
(2000)  of 21-day cycle
Takeda et al  1.0 mg/m2 days 1–5  26  37.4  92  40  46
(2003)  of 21-day cycle
Shipley et al  4.0 mg/m2 weekly  5  19.4  21  27  NR
(2006)  for 12 weeks
Murphy et al  4.0 mg/m2 weekly  13  22.4  29  8  NR
(2006)  for 12 weeks    (in patients 
     with  PR/SD)
Ardizzoni et al  Topotecan, 0.75 mg/m2 on  27  S: 27.5,   S: 76,   S: 74,  S: 37,
(2003)  days 1–5; cisplatin, 60 mg/m2    R: 26.2  R: 74  R: 63  R: 40
   on day 1 every 21-days
Christodoulou  Topotecan, 0.9 mg/m2; cisplatin,  18  28.0  42  15  15
et al (2006)  20 mg/m2 on days 1–3 every
 21-days
Note: aPooled retrospective analysis of 5 phase II and III trials; bSurvival times were reported based on patient performance status; cResults reported as percentage of courses.
Abbreviations: ORR, Overall response rate; mOS, Median overall survival; NR, Not reported; S, Chemosensitive;  R, Chemorefractory; PR, Partial response; SD, Stable disease. Therapeutics and Clinical Risk Management 2007:3(6) 1093
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Combination regimens
The goal of combination therapy in the treatment of SCLC is 
to promote synergistic antitumor activity in an attempt to yield 
a higher ORR and an improved duration of response compared 
with the results obtained with monotherapy. However, combi-
nation therapies may be associated with increased incidence of 
overlapping toxicities, and it is unclear whether these regimens 
are more effective than single-agent therapies in the treatment 
of recurrent SCLC. Multiple clinical trials with a number of 
investigational drug combinations and schedules have been 
undertaken to determine the beneﬁ  t of topotecan combination 
therapy in the treatment of recurrent SCLC.
A phase II trial of second-line topotecan (0.75 mg/m2 
on days 1 to 5 of a 21-day cycle) in combination with cis-
platin (60 mg/m2 on day 1) was conducted in patients with 
either refractory or sensitive SCLC (N = 110) (Ardizzoni 
et al 2003). The ORR was 27% (chemosensitive SCLC, 
29%; chemorefractory SCLC, 24%) (Ardizzoni et al 2003). 
Despite differences in response rates, mOS was similar 
between patients with chemosensitive SCLC and patients 
with chemorefractory SCLC (chemosensitive, 6.4-months 
[27.5 -weeks]; chemorefractory SCLC, 6.1-months [26.2-
weeks]) (Ardizzoni et al 2003). The most prevalent and 
severe toxicity was myelosuppression, with grade 4 neutrope-
nia occurring in 62% of patients with chemosensitive SCLC 
and 49% of patients with chemorefractory SCLC (Ardizzoni 
et al 2003). Nonhematologic toxicities were generally mild, 
with grade 3/4 nausea, vomiting, and diarrhea occurring 
in 10% of all patients (Ardizzoni et al 2003). The most 
commonly reported nonhematologic adverse event was 
fatigue/malaise, which occurred in 52% of chemosensitive 
patients and 68% of chemorefractory patients (Ardizzoni et al 
2003). Therefore, based on this phase II trial, topotecan and 
cisplatin combination therapy is active and tolerable in the 
second-line treatment of SCLC (Ardizzoni et al 2003).
Combination therapies with alternative topotecan dos-
ing schedules have also been investigated for the treatment 
of SCLC. In a phase II trial of topotecan (0.9 mg/m2) and 
cisplatin (20 mg/m2) administration on days 1 to 3 every 
3-weeks in patients with recurrent SCLC (N = 34), the ORR 
Figure 3 Overall response rates (ORRs) and stable disease (SD) responses to various topotecan treatment regimens.Therapeutics and Clinical Risk Management 2007:3(6) 1094
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was 18%, with chemosensitive patients experiencing a greater 
overall response (24%) compared with chemorefractory 
patients (8%; Christodoulou et al 2006). The mOS and time to 
progression for the entire patient population were 6.5-months 
(28.0-weeks) and 4.4-months (18.9-weeks), respectively, 
although patients with chemosensitive disease had a longer 
mOS (chemosensitive SCLC, 7.8-months [33.5-weeks]; 
chemorefractory SCLC, 6.2-months [26.7-weeks]) and 
time to progression (chemosensitive SCLC, 5.9-months 
[25.4-weeks]; chemorefractory SCLC, 3.2-months 
[13.8-weeks]) than patients with chemorefractory disease 
(Christodoulou et al 2006). This regimen was well tolerated, 
and grade 3/4 neutropenia, anemia, and thrombocytopenia 
occurred in 42%, 15%, and 15% of patients, respectively 
(Christodoulou et al 2006). Alopecia was the most common 
nonhematologic toxicity, occurring in 6% of patients 
(Christodoulou et al 2006). This 3-day schedule of topotecan 
and cisplatin provides patients with SCLC that is either che-
mosensitive or chemorefractory with a tolerable, efﬁ  cacious, 
and potentially more convenient treatment regimen.
The administration of weekly topotecan has also been 
combined with a number of chemotherapeutic agents 
including taxanes, temozolomide, and platinum agents. For 
example, a phase II trial of weekly topotecan (1.75 mg/m2) 
plus paclitaxel (70 mg/m2) was conducted in patients with 
recurrent SCLC (N = 41) (Stathopoulos et al 2006). The ORR 
of 27% was similar to that reported for single-agent topote-
can therapy (Stathopoulos et al 2006). The median duration 
of response and mOS were 4.0-months (17.2-weeks) and 
7.0-months (30.1-weeks), respectively (Stathopoulos et al 
2006). Myelosuppression was the most commonly reported 
adverse event, with grade 3/4 neutropenia occurring in 27% 
of patients (Stathopoulos et al 2006).
Although topotecan combination therapies appear to be 
active in recurrent SCLC, response rates are similar to those 
reported in response to topotecan monotherapy. The role of 
topotecan combination therapies for the treatment of patients 
with SCLC remains to be determined.
Discussion
Small cell lung cancer is an aggressive malignancy that has 
a high response rate to standard ﬁ  rst-line therapies but typi-
cally relapses. Recurrent SCLC has a poor prognosis and is 
generally poorly responsive to therapies. Moreover, patients 
with recurrent SCLC often have comorbidities. In this setting, 
disease stabilization is considered a treatment beneﬁ  t, and 
symptom palliation is an important goal. Antitumor activity 
must be balanced with tolerability to maximize QOL. Patients 
with renal impairment and depletion of bone marrow reserves 
from prior chemotherapy exposure may be predisposed to 
adverse events. Topotecan provides an attractive therapeutic 
option for the treatment of SCLC in this setting because it is 
active and well tolerated, is not associated with cumulative 
toxicity, and offers ﬂ  exible dosing and treatment schedules 
to accommodate patients with comorbidities or concurrent 
therapy. The reversible and noncumulative hematologic 
toxicities and mild to moderate nonhematologic toxicities 
may help to preserve a patient’s QOL during long-term 
treatment.
Alternative dosing regimens and treatment schedules 
have demonstrated promising antitumor activity and may 
provide improved tolerability and patient convenience 
beneﬁ  ts compared with the standard 5-day regimen. These 
alternative regimens may be especially beneﬁ  cial for patients 
at high risk for myelosuppression, including patients who 
have impaired renal function, advanced age, or a history 
of multiple rounds of chemotherapy. Although topotecan-
containing combination therapies have not yet demonstrated 
greater efﬁ  cacy compared with monotherapy in the treatment 
of relapsed SCLC, trials are ongoing to optimize combina-
tions and treatment schedules.
In conclusion, topotecan provides physicians with an 
effective and ﬂ  exible therapeutic option for the treatment of 
recurrent SCLC. Further studies to investigate optimal topo-
tecan treatment strategies are warranted and should focus on 
improving survival and preserving QOL while maintaining 
efﬁ  cacy. These issues are important to patients undergoing 
long-term treatment for SCLC, especially those who may not 
be able to tolerate aggressive therapeutic regimens.
Future directions
Preliminary studies are underway to investigate alternative 
treatment strategies that may further enhance a patient’s 
response to topotecan therapy. One such approach involves 
administering an induction dose of topotecan to sensitize 
tumors to subsequent standard therapies. The activity of 
topotecan in SCLC makes it well suited for use as induction 
therapy. Moreover, its unique mechanism of action decreases 
the likelihood of cross-resistance to other therapies. This 
induction-based approach has previously displayed favor-
able activity when cyclophosphamide, epiadriamycin, and 
vincristine were used for induction therapy before platinum-
based chemotherapy and concurrent radiotherapy in patients 
with limited SCLC in a phase II trial (Maranzano et al 2002). 
Moreover, in a phase I trial of chemotherapy-naive patients 
with SCLC, induction therapy with topotecan was well Therapeutics and Clinical Risk Management 2007:3(6) 1095
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tolerated and produced partial responses both in patients with 
limited-stage disease and in patients with extensive-stage 
disease (Garst et al 2006). Consistent with the tolerability 
proﬁ  le of single-agent topotecan, the dose-limiting toxicity 
in this regimen was myelosuppression (Garst et al 2006). 
The maximum tolerated dose of topotecan was 2.25 mg/m2 
on days 1 to 3 of a 2-week cycle with G-CSF support (Garst 
et al 2006). Nonhematologic toxicities were generally not 
severe and included anorexia, nausea, and 1 renal adverse 
event (Garst et al 2006).
Individual dose adjustments are also under investiga-
tion to reduce toxicities for each patient receiving treatment 
(Huber et al 2006). This type of personalized approach to 
patient therapy should allow physicians to determine the 
maximum tolerated dose for each patient while minimizing 
toxicity and maintaining efﬁ  cacy. Preliminary results using 
this individualized approach have been positive in patients 
with SCLC (Huber et al 2006).
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